Cargando…

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor

Detalles Bibliográficos
Autores principales: Yim, Eunjung, An, Ho Jung, Cho, Uiju, Kim, Youngwoo, Kim, Seung Hoon, Choi, Yeon-Geun, Shim, Byoung Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840584/
https://www.ncbi.nlm.nih.gov/pubmed/27384439
http://dx.doi.org/10.3904/kjim.2015.295
_version_ 1783304606775771136
author Yim, Eunjung
An, Ho Jung
Cho, Uiju
Kim, Youngwoo
Kim, Seung Hoon
Choi, Yeon-Geun
Shim, Byoung Yong
author_facet Yim, Eunjung
An, Ho Jung
Cho, Uiju
Kim, Youngwoo
Kim, Seung Hoon
Choi, Yeon-Geun
Shim, Byoung Yong
author_sort Yim, Eunjung
collection PubMed
description
format Online
Article
Text
id pubmed-5840584
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Korean Association of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-58405842018-03-08 Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor Yim, Eunjung An, Ho Jung Cho, Uiju Kim, Youngwoo Kim, Seung Hoon Choi, Yeon-Geun Shim, Byoung Yong Korean J Intern Med Letter to the Editor The Korean Association of Internal Medicine 2018-03 2016-07-07 /pmc/articles/PMC5840584/ /pubmed/27384439 http://dx.doi.org/10.3904/kjim.2015.295 Text en Copyright © 2018 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Yim, Eunjung
An, Ho Jung
Cho, Uiju
Kim, Youngwoo
Kim, Seung Hoon
Choi, Yeon-Geun
Shim, Byoung Yong
Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
title Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
title_full Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
title_fullStr Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
title_full_unstemmed Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
title_short Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
title_sort two different kit mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840584/
https://www.ncbi.nlm.nih.gov/pubmed/27384439
http://dx.doi.org/10.3904/kjim.2015.295
work_keys_str_mv AT yimeunjung twodifferentkitmutationsmayleadtodifferentresponsestoimatinibinmetastaticgastrointestinalstromaltumor
AT anhojung twodifferentkitmutationsmayleadtodifferentresponsestoimatinibinmetastaticgastrointestinalstromaltumor
AT chouiju twodifferentkitmutationsmayleadtodifferentresponsestoimatinibinmetastaticgastrointestinalstromaltumor
AT kimyoungwoo twodifferentkitmutationsmayleadtodifferentresponsestoimatinibinmetastaticgastrointestinalstromaltumor
AT kimseunghoon twodifferentkitmutationsmayleadtodifferentresponsestoimatinibinmetastaticgastrointestinalstromaltumor
AT choiyeongeun twodifferentkitmutationsmayleadtodifferentresponsestoimatinibinmetastaticgastrointestinalstromaltumor
AT shimbyoungyong twodifferentkitmutationsmayleadtodifferentresponsestoimatinibinmetastaticgastrointestinalstromaltumor